Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ICML 2019 | CLL12: ibrutinib monotherapy upfront, a potential competitor for ‘watch-and-wait’?

Michael Hallek, MD, PhD, University of Cologne, Cologne, Germany, discusses the CLL12 trial (NCT02863718) of ibrutinib compared to a placebo in asymptomatic, untreated chronic lymphocytic leukemia (CLL). This interview took place at the 15th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland.